MedPath

Ocuphire Pharma

Ocuphire Pharma logo
🇺🇸United States
Ownership
Public
Established
2018-02-01
Employees
14
Market Cap
$31.9M
Website
http://www.ocuphire.com
Introduction

Ocuphire Pharma, Inc. engages in the research and development of ophthalmic biopharmaceutical products. It focuses on developing and commercializing therapies for the treatment of several eye disorders. The company was founded by Mina Patel Soouch and Alan R. Meyer in February 2018 and is headquartered in Farmington Hills, MI.

Clinical Trials

13

Active:2
Completed:11

Trial Phases

2 Phases

Phase 2:6
Phase 3:7

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (13 trials with phase data)• Click on a phase to view related trials

Phase 3
7 (53.8%)
Phase 2
6 (46.2%)

Evaluate Efficacy and Safety of POS to Improve Distance-corrected Near Visual in Participants With Presbyopia

Phase 3
Active, not recruiting
Conditions
Presbyopia
Interventions
First Posted Date
2024-08-07
Last Posted Date
2025-07-22
Lead Sponsor
Ocuphire Pharma, Inc.
Target Recruit Count
545
Registration Number
NCT06542497
Locations
🇺🇸

United States, San Antonio, Texas, United States

Safety and Efficacy of 0.75% Phentolamine Ophthalmic Solution in Subjects With Post-refractive Surgery Visual Disturbances

Phase 3
Active, not recruiting
Conditions
Mesopic Vision
Night Vision Loss
Interventions
First Posted Date
2024-04-05
Last Posted Date
2025-07-24
Lead Sponsor
Ocuphire Pharma, Inc.
Target Recruit Count
200
Registration Number
NCT06349759
Locations
🇺🇸

United States Phoenix, Phoenix, Arizona, United States

🇺🇸

United States Scottsdale, Scottsdale, Arizona, United States

🇺🇸

United States, Tampa, Florida, United States

and more 19 locations

Safety and Efficacy of Nyxol Eye Drops as a Single Agent and With Adjunctive Low-Dose Pilocarpine Eye Drops in Subjects With Presbyopia

Phase 3
Completed
Conditions
Presbyopia
Interventions
Other: Placebo
Other: Low dose pilocarpine vehicle
First Posted Date
2022-12-12
Last Posted Date
2025-08-01
Lead Sponsor
Ocuphire Pharma, Inc.
Target Recruit Count
333
Registration Number
NCT05646719
Locations
🇺🇸

Phoenix, AZ, Phoenix, Arizona, United States

🇺🇸

Azusa, CA, Azusa, California, United States

🇺🇸

Newport Beach, CA, Newport Beach, California, United States

and more 23 locations

Nyxol (0.75% Phentolamine Ophthalmic Solution) to Reverse Pharmacologically-Induced Mydriasis in Pediatric Subjects

First Posted Date
2022-02-04
Last Posted Date
2023-09-05
Lead Sponsor
Ocuphire Pharma, Inc.
Target Recruit Count
23
Registration Number
NCT05223478
Locations
🇺🇸

Clinical Site 1, Longwood, Florida, United States

🇺🇸

Clinical Site 2, Athens, Ohio, United States

Safety and Efficacy of Nyxol (0.75% Phentolamine Ophthalmic Solution) to Reverse Pharmacologically-Induced Mydriasis (MIRA-3)

First Posted Date
2021-11-26
Last Posted Date
2023-08-29
Lead Sponsor
Ocuphire Pharma, Inc.
Target Recruit Count
368
Registration Number
NCT05134974
Locations
🇺🇸

Clinical Site 10, Newport Beach, California, United States

🇺🇸

Clinical Site 12, Westminster, California, United States

🇺🇸

Clinical Site 9, Delray Beach, Florida, United States

and more 12 locations
  • Prev
  • 1
  • 2
  • 3
  • Next

News

Advancements in Clinical Trials for Fabry Disease, C. difficile Infections, and Mydriasis

• Clinical trials are actively progressing for Fabry Disease, with companies like Idorsia and Sanofi Genzyme developing novel therapies. • Emerging treatments like Venglustat and Pegunigalsidase alfa are expected to significantly impact the Fabry Disease market in the coming years. • Research and development efforts are also focused on Clostridium Difficile Infections, with Vedanta Biosciences leading Phase 3 trials for VE303. • Mydriasis treatments are advancing, with companies like Eyenovia exploring solutions like MYDCOMBI for pupil dilation.

Ocuphire Pharma Acquires Opus Genetics, Expanding Gene Therapy Pipeline for Inherited Retinal Diseases

Ocuphire Pharma has acquired Opus Genetics in an all-stock transaction, with the combined company renamed Opus Genetics, Inc., focusing on inherited retinal diseases.

Phentolamine Ophthalmic Solution (Ryzumvi) Demonstrates Efficacy in Reversing Mydriasis in Phase 3 Trials

Phentolamine ophthalmic solution 0.75% (Ryzumvi) significantly reversed pharmacologically-induced mydriasis in MIRA-2 and MIRA-3 Phase 3 trials.

Ocuphire Pharma Initiates Phase 3 Trial of Phentolamine Ophthalmic Solution for Presbyopia

Ocuphire Pharma has dosed the first patient in its Phase 3 VEGA-3 clinical trial evaluating phentolamine ophthalmic solution 0.75% for presbyopia.

Ocuphire Pharma Initiates Phase 3 VEGA-3 Trial of Phentolamine Ophthalmic Solution for Presbyopia

Ocuphire Pharma has dosed the first patient in its Phase 3 VEGA-3 clinical trial evaluating phentolamine ophthalmic solution 0.75% for presbyopia.

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.